Home › Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA (pembrolizumab)
 

Keywords :   


Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA (pembrolizumab)

2015-05-28 14:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & SEATTLE Collaboration Builds on Mercks R&D and NanoStrings Biomarker Development Leadership Positions in Immuno-Oncology Early Data Evaluating Immune-Related Signatures with KEYTRUDA in Multiple Cancers to be Presented for the First Time at 2015 ASCO Annual Meeting KENILWORTH, N.J. & SEATTLE--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NanoString Technologies, Inc. (NASDAQ:NSTG) today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in multiple tumor types. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orMerck Investor Relations:Justin Holko, 908-740-1879orNanoString Investor/Media Relations:Leigh Salvo, 415-513-1281 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NSTG Exchange: NASDAQ read more

Tags: for research development program

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.09Australia supermarkets sued over fake discount claims
23.09Tropical Depression Ten-E Public Advisory Number 1A
23.09Summary for Tropical Depression Ten-E (EP5/EP102024)
23.09Tropical Depression Ten-E Graphics
23.09Eastern North Pacific Tropical Weather Outlook
23.09Atlantic Tropical Weather Outlook
22.09Tropical Depression Ten-E Forecast Discussion Number 1
22.09Tropical Depression Ten-E Graphics
More »